IDENTIFYING THE RISK OF ALZHEIMER’S DISEASE: A CASE FOR PREVENTION VERSUS MAINTENANCE
An interview with Dr. N.P. Vasavan Nair, of the Douglas Hospital
by Angela J. Ring

Dr. Neelakanta Pillai (N.P.) Vasavan Nair came to the Douglas Hospital in 1972 from Saskatchewan with the intention of studying schizophrenia and depression. Little did he know at that time that he would become one of the leading researchers at the Douglas Hospital. A quick look at his profile on the Douglas website only serves to underscore the impact of his presence in the hospital. Over the years he has served as Director of Research Services, Director of the Douglas Hospital Research Centre, Director of the Department of Psychiatry, and Medical Director for the Program for Dementia with Psychiatric Comorbidity, among many other accomplishments too long to list here.

When asked about his research, Dr. Nair chooses to discuss an on-going project started in 1983. He draws attention to the point that at that time, there wasn’t much hope for treatment of Alzheimer’s Disease (AD), but that prevention was thought a viable option. As such, Dr. Nair and his team of researchers were interested in detecting possible markers of risk for AD. Identifying early risk markers can be key when dealing with AD, since memory systems have many backups, and as such people are able to compensate for quite some time before they notice any real change in functioning. Often by the time that people start noticing or complaining of memory difficulties, they are past the point of prevention.

The team of researchers began by recruiting healthy older adults between the ages of 60 and 90. Based on epidemiological studies they estimated that approximately 5-15% of their sample would likely develop AD. They then administered a test battery consisting of standard neuropsychological tests, endocrine measures such as cortisol levels, and memory testing.

(Continued on page 2)
and melatonin, and CT scans. The idea was that by combining a variety of different measures, there would be an increase in sensitivity of the various tests. The test battery was administered to participants yearly to see what if anything would change over time, and if any of the changes were associated with the onset of AD.

Over the years Dr. Nair’s team has found that an increase in cortisol levels is associated with mild cognitive decline, and that a decrease in melatonin levels is associated with a decrease in episodic memory. From these findings the team concluded that an increase in cortisol and a decrease in melatonin might be indications for possible risk of AD. Dr. Nair also points out that since the study began, other markers have been identified such as the apolipoprotein (apo) E4 allele. In light of this, Dr. Nair would like to develop a “package” of tests in order to create a standardized battery to be used in formal risk assessment. This battery would include neuropsychological testing, genetic testing, fMRI scans, and endocrine measures that combined would aid in identifying those people at greater risk for AD.

By developing a test battery for identifying those at risk, it would be possible to engage these individuals in preventative programs aimed at either delaying the onset of AD or reducing the severity of symptoms. This is particularly important for relatives of those with AD who often worry about what can be done for them. This feeling is now being reflected among many organizations such as the National Institutes of Health (NIH) that now largely concern themselves with developing prevention programs. Dr. Nair also draws from an example in Sweden where a community-based prevention program has shown successful results in reducing the incidence of AD.

He points out that at the governmental level, prevention is not viewed as the mandate of hospitals, and therefore funding for these kinds of programs can be scarce. Dr. Nair cautions that this can be a dangerous stance to take. With an aging world population, and particularly in communities that have a higher proportion of older adults, prevention will be key in managing the disease, both on a personal and economic level. The more people that can be helped in staving off the onset of AD, or in reducing the severity of symptoms, the fewer people there will be occupying hospital wards. Thus, prevention is not only helpful for those that seek it, but also cost-effective in the long run.

What would a prevention program involve exactly? In large part it would involve educating the community about AD and prevention. On a more individual level, in most cases it would involve regular visits to a clinic with the aim of teaching specific strategies for prevention. These strategies might include stress reduction techniques to target high cortisol levels, as well as diet and exercise. The program might also aim to teach intellectual activities such as crosswords or chess to “keep the mind active”. Dr. Nair points out that some of the findings of this research still need to be explored further, and may lead to other kinds of strategies for AD. He draws attention to the decreased melatonin findings, which may suggest a decreased sensitivity to light. Although this remains a hypothesis, if it turns out to be the case it may be possible to develop a “light treatment” of sorts to be used in conjunction with other preventative strategies. In the end though, the kinds of activities that might be prescribed will vary greatly from one individual to the next, but the basic principle will remain the same. By visiting a prevention program a few times per year, it may be possible to delay or even avoid hospitalization for AD, thus benefiting everyone involved.
W
take”.
withdrawal is the responsible course to
data, we concluded that a voluntary
therapies and the questions raised by the
data, given the availability of alternative
labelling that would incorporate these new
possible to continue to market Vioxx with
“Although we believe it would have been
officer had this to say when the news broke.
Ray Gilmartin, Merck’s chief executive
makers of Vioxx, Merck, showed that heart
pulling in global sales of 2.5 billion in 2003.
In fact, Vioxx was
extremely well received when they burst
and ibuprofen), COX-2 inhibitors were
with extended use of NSAIDS (e.g. aspirin
and ibuprofen), COX-2 inhibitors were extremely well received when they burst
onto the market in 1999. In fact, Vioxx was
onto the market. Interestingly, the panel was
comprised of both arthritis patients and
medical experts.

Some background on COX-2 inhibitors
COX-2 inhibitors were initially designed to
provide pain relief without causing any of
the gastrointestinal problems that come
about with the use of traditional NSAIDS
(non-steroidal anti-inflammatory drugs).
NSAIDS target two enzymes in the body, the
one that causes arthritis pain and swelling
(COX-2) and the other that protects the
lining of the stomach (COX-1). COX-2
inhibitors such as Celebrex, Vioxx, Bextra,
and Mobicox were designed to only block
the actions of the enzyme that causes
arthritis pain and inflammation. Given that
many arthritis patients ended up with
bleeding in the stomach lining and/or ulcers
with extended use of NSAIDS (e.g. aspirin
and ibuprofen), COX-2 inhibitors were extremely well received when they burst
onto the market in 1999. In fact, Vioxx was
pulling in global sales of 2.5 billion in 2003.
Then a clinical trial conducted by the
makers of Vioxx, Merck, showed that heart
conditions and cardiovascular complications
could occur after 18 months of Vioxx use. It
was taken off the market in October 2004.
Ray Gilmartin, Merck’s chief executive
officer had this to say when the news broke.
"Although we believe it would have been
possible to continue to market Vioxx with
labelling that would incorporate these new
data, given the availability of alternative
therapies and the questions raised by the
data, we concluded that a voluntary
withdrawal is the responsible course to
take”.

What Canadians had to say on the matter
Health Canada received 48 written
submissions from patients and patient
advocates. Impressively, 44 of the 48 were
favourable to a return of COX-2 inhibitors to
the Canadian market. One of the arthritis
patients chosen for the June 9th panel,
Michael Hynes, said “Your
recommendations have the ability to
maintain or destroy my life, as Celebrex is
the only drug that gives me enough pain
relief to get out of bed”. In contrast,
Kassandra Poirier, 19, discouraged the
return of COX-2 inhibitors after her
54-year-old mother died of a heart attack as
a result of taking Vioxx for 3 months. "It's a
personal choice,” said Poirier. "I think if my
mother knew all the risks of taking a drug
like that, being a single parent I don't think
she would have.” One patient and panelist
suffering from rheumatoid arthritis
Huguette Labrie wrote “We as patients all
make informed choices in collaboration
with our doctors and that should never be
taken away from us… Sometimes, quality of
life takes precedent over quantity. Let the
people that need the drugs decide for
themselves, which they prefer. I for one will
choose quality over quantity any day”.

Panel recommendations
On the day of the hearing, Health Canada
was first presented with the scientific
evidence from the expert panel and then
with the testimonials of arthritis patients
and/or their loved ones. In the end, the
panel's report consisted of answers to
specific questions posed by Health Canada
along with their recommendations with
respect to the re-entry of COX-2 inhibitors
on the Canadian market.

In summary, the panel was convinced
that although all COX-2 inhibitors increase
the risk of cardiovascular events, the
scientific evidence available justifies the
marketing of Celebrex (vote: 13 yes 0 no),
and Vioxx in Canada (vote: 12 yes, 1 no).
They argued that the increased
cardiovascular risks caused by Celebrex and
Vioxx were similar to that of most NSAIDS,
and that the risk of gastrointestinal harm
appears to be less than most NSAIDS.
Moreover, patients definitely benefit from
having a variety of drugs to choose from for
pain relief. Bextra on the other hand, was not
approved for marketing in Canada (5 yes, 8
no) because of the paucity of information on
the long-term cardiovascular risks
associated with the drug and because there
are increased risks of severe skin reactions.
Thus, they felt that the overall benefits
outweighed the risks for most patients but
cautioned that “The appropriate use of these
drugs must, as with all drugs, be influenced
by the individual circumstances of each
patient, and how they value the benefits and
harms of the drugs. In the end, this decision
should be left to informed patients, advised
by their well-educated healthcare
providers”.

The expert panel put forth several
recommendations to Health Canada that
would ensure the most appropriate use of
COX-2 inhibitors. They strongly
recommended that complete transparency be
implemented at every level, including
appropriate warnings about the risks of
COX-2 inhibitors added to the product
material given to the patient, providing the
public with easy access to unbiased
information about these drugs (internet,
pharmacy, or doctor’s office), and a
continued ban on direct-to-consumer
advertising by those who profit financially
from these drugs.

The experts also suggested that
individuals buying over-the-counter
NSAIDS such as ibuprofen should first
meet with a pharmacist so that he/she may
explain the risks involved and correct
dosage and use of the drugs. Finally, the
panel unanimously felt that ALL data related
to a drug, both published and unpublished,
should be publicly available in an
easy-to-access format and that certain
Canadian regulations should be modified to
ensure that all material submitted to Health
Canada surrounding drug licensing requests
(as well as Health Canada’s assessment of
that drug) be made public. Policy changes
such as these could make a big difference
down the line. As it stands now, drug
manufacturers are not held to disclose all the
respective websites, one can find a variety of thoughtful, helpful and very well prepared articles and information sheets on many a topic of interest to Canada’s aging population.

For instance, the Aging and Seniors Division publishes information sheets relating to arthritis, stroke, heart disease, vision, diabetes, and osteoporosis, to name a few aging-associated diseases. These sheets provide tips and information tailored to what seniors want to know, and don’t beat around the bush. The no-nonsense style is characterized by stating what the disease or condition is, what are its warning signs, what are its risk factors, how it is prevented, how to cope, and where to find more information. In short, the Info-Sheets for Seniors are one stop shopping for aging-related knowledge. Also, it is comforting that the information comes from a trusted source.

But diseases of aging are not the only topics covered by the websites. For example, in the most recent issue of Expressions, the bulletin of the National Advisory Council on Aging, there is a great exposé written concerning grandparenting in today’s Canadian society. Indeed, as many Geronto-McGill readers are fully aware, the role of the grandparent has shifted as society has changed. The article provides a detailed and practical overview of today’s Canadian grandparent and is definitely worth the read.

Other issues of this superb publication concern medication use among elders, grieving, and the myths of aging and sex over 60. Clearly, there are a variety of topics to choose from the pages of Expressions, and rest assured that all are well researched and clearly presented.

For access to these numerous resources, all one needs is a computer and a connection to the Internet. If you do not have a computer, public libraries often offer such services, and maybe your kids could help out… Otherwise, the Aging and Seniors Division of the Public Health Agency of Canada, as well as the National Advisory Council on Aging, can be contacted directly by telephone. See below for web and mail addresses, and for telephone numbers. Happy web surfing!

For a list of aging-related documents published by the Aging and Seniors Division of the Public Health Agency of Canada, visit
http://www.hc-sc.gc.ca/seniors-aines/index_pages/publications_e.htm#living

For the Info-Sheets for Seniors, visit
http://www.hc-sc.gc.ca/seniors-aines/pubs/info_sheets/intro_e.html

For a list of aging-related documents published by the National Advisory Council on Aging, visit
http://www.naca-ccnta.ca/publications_e.htm#challenge

For Expressions visit
http://www.naca-ccnta.ca/expression/expintro_e.htm

Mail address, telephone numbers and email
National Advisory Council on Aging
Address locator: 1908A1 Ottawa, ON K1A 1B4
Tel.: 613-957-1968
Fax : 613-957-9938
E-mail: info@naca-ccnta.ca

Division of Aging and Seniors Public Health Agency of Canada
Address Locator 1908A1 Ottawa, Ontario
K1A 1B4
Telephone: (613) 952-7606
Fax: (613) 957-9938
E-mail: seniors@phac-aspc.gc.ca

AGING INFO ONLINE COURTESY OF THE CANADIAN GOVERNMENT: A GREAT RESOURCE AT YOUR FINGERTIPS

(Continued from page 1)

emotions. After all, time is precious, why hold a grudge? So, what may appear as a decline in cognitive abilities for some could in fact be evidence that many things get better with age, including emotional memory, which by many accounts, may be more important to many older adults out there.


SOME THINGS JUST GET BETTER WITH AGE

(Continued from page 2)
information and data they have gathered on a given drug. The Health Canada news release stated: “The Minister has clearly stated his preference for full disclosure, with the exception of legitimate and compelling reasons of privacy or business confidentiality”.

Health Canada’s response to the report
Canada’s Health Minister Ujjal Dosanjh said: “We welcome the panel’s report and I’d like to thank the public for its contribution… This is the first time that the Canadian public has been invited to participate in a Health Canada expert advisory panel. Health Canada supports the direction of the Panel’s recommendations. Openness and transparency will become a way of doing business in the Department”. Immediate actions Health Canada promised to take were to ensure that manufacturers of all NSAIDS provide updated patient safety information for these products and promised to issue guidance to these manufacturers by establishing standards for the risk and benefit information that must be included in product labelling. Health Canada will also establish open communication with health care professionals and the public keeping them informed about the safety of the drugs in question. Health Canada also promised to further evaluate issues surrounding the availability of over-the-counter medications and their potential inappropriate long-term use. The Minister was also pleased to announce a new Web-based database on adverse drug reactions in Canada: http://www.hc-sc.gc.ca/dhp-mps/medeff/database/index_e.html.

Clearly, Health Canada and the manufacturers of arthritis medications have their work cut out for them but in the meantime, many arthritis sufferers and their doctors have much to celebrate. Indeed, thanks are in order for the outspoken Canadians who, alongside the experts, fought for the return of COX-2 inhibitors. When we really want to, we can truly make a difference.

Sources
Panel report:

CBC news:

Health Canada Press Release:

We’ve all heard the saying that with age comes wisdom, but what does this really imply? One area of life that would certainly benefit from a little bit of wisdom is in our interpersonal relationships, particularly when those relationships are conflictual. With this question on mind, a team of researchers from University of Michigan and Purdue University asked the question: “Do we get better at picking our battles” as we age?

The researchers interviewed volunteers between the ages of 13 and 99, and asked them to describe some of their interpersonal relationships and how they reacted to a recent conflict within those relationships. They analyzed what the participants told them using a framework of conflict strategies based on two dimensions. These dimensions include active or passive strategies and constructive or destructive strategies. For example, active constructive (Voice) strategies for conflict resolution might include listening or discussing the problem, while active destructive (Exit) strategies would include yelling, name-calling or physical aggression. In terms of passive strategies for conflict resolution, constructive (Loyalty) ones might include remaining calm and waiting for the situation to blow over, while destructive (Neglect) strategies might include avoiding the person or sulking.

The older adults in this study tended to rely more heavily on “Loyalty” strategies such as remaining calm and waiting for the situation to blow over than were their younger counterparts. In fact, the younger participants were more likely to use “Exit” strategies such as arguing or yelling, which are viewed as destructive interpersonal strategies. In addition, the authors found support for the notion that as we age, we experience fewer interpersonal problems, feel less negative emotions, and are better able to regulate our emotional responses to interpersonal difficulties. Thus, it appears as if we do in fact get wiser with age, and that those of us still in the earlier stages of life might be able to learn a thing or two from those that have walked before us.

SCIENCE HERE AND NOW
GROWTH HORMONE AND AGING:
THE PASSION OF PIERRETTE GAUDREAU
by Daniel Auld

Pierrette Gaudreau, Ph.D., is the head of the Laboratory of Neuroendocrinology of Aging at the University of Montreal. When it comes to the basic biology behind aging, her lab is one of Montreal’s most active. Dr. Gaudreau is particularly interested in the actions of Growth Hormone (GH), a hormone that promotes growth and helps control the body’s metabolism. In addition to well-known roles during development, GH is involved in tissue repair and maintenance in adults.

When the body needs GH, a part of the brain called the hypothalamus secretes another hormone called Growth Hormone Releasing Hormone (GHRH). GHRH tells a gland called the pituitary to make and release GH into the blood. In middle and late adulthood, GH levels drop compared to young adults and children. Scientists believe lowered GH levels contribute to features of aging, including loss of muscle mass and greater fat deposition. Dr. Gaudreau’s research team has shown that by giving aged rats extra GHRH, which causes increased GH release, it is possible to have the old rat’s hormonal system looking like a young rat’s again. Thus, her research is important because it suggests that GHRH might effectively increase GH level in older humans.

Dr. Gaudreau has also studied the effect of aging on diet and eating. As we age, our appetite and food intake typically decrease. A very similar profile of reduced eating occurs in aged rats. Dr. Gaudreau’s team found that injecting GH into old rats, in order that they had a level similar to that of young rats, resulted in a drastic improvement in food intake. This suggests that restoring GH levels to similar-to-young levels might help older humans suffering from loss of appetite.

In more recent work, Dr. Gaudreau has shifted her attention to cancer. A protein called insulin-like growth factor-1 (IGF-1) has been linked to cancer progression. It just so happens that the hormone Dr. Gaudreau knows most about, namely GH, increases synthesis and release of IGF-1. Other research has shown that by inhibiting GHRH, which normally increases GH release, cancer progression can be slowed, presumably by reducing IGF-1 levels. In order to better understand how GHRH might slow cancer growth, scientists need to know in what part of the body the GHRH is acting. Dr. Gaudreau and her colleagues have contributed to this effort by showing that GHRH receptors – which are the site of GHRH action – are present in both human male and female reproductive systems. Given the role of GHRH in prostate and breast cancer progression, knowing its exact sites of action will surely be information that scientists can use to better understand these cancers, and hopefully use it to design cures.

Peptides 22: 2119–2126
